

December 7, 2012

Celldex Therapeutics Announces Upcoming Presentation at Oppenheimer Healthcare Conference

NEEDHAM, Mass.--(BUSINESS WIRE)-- <u>Celldex Therapeutics, Inc.</u> (NASDAQ: CLDX) announced today that Anthony Marucci, President and Chief Executive Officer, is scheduled to present a corporate overview at the Oppenheimer 23rd Annual Healthcare Conference on Wednesday, December 12, 2012 at 10:00 am ET at the Waldorf=Astoria in New York City.

A <u>live webcast</u> of the presentation will be available online on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. A replay of the presentation will be available for 30 days following the event.

About Celldex Therapeutics, Inc.

Celldex Therapeutics is the first antibody-based combination immunotherapy company. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy (PTI) Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates. For more information, please visit <u>www.celldextherapeutics.com</u>.

Celldex Therapeutics, Inc. Sarah Cavanaugh, 781-433-3161 Vice President of IR & Corp Comm scavanaugh@celldextherapeutics.com or For Media: BMC Communications Brad Miles, 646-513-3125 bmiles@bmccommunications.com

Source: Celldex Therapeutics, Inc.

News Provided by Acquire Media